Evidence map›Paper›PMID 41573680›Full record

ArticleFrontiers in cell and developmental biology2025

CGR11 promotes hepatocellular carcinoma progression by regulating autophagy through the PI3K/AKT pathway.

Jia Zhou, Sulai Liu, Yinghui Song, Junjie Liu, Zhiguo Tan, Jie Liu, Xiaoxia Han, Yang Xing, Xinrun Wang, Chuang Peng and 2 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jia ZhouThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Sulai LiuDepartment of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
Yinghui SongDepartment of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
Junjie LiuDepartment of General Surgery, Hunan Aerospace Hospital, Changsha, China.
Zhiguo TanThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Jie LiuThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Xiaoxia HanThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Yang XingThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Xinrun WangThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Chuang PengDepartment of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
Bo SunDepartment of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
Yufang LengThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC), the predominant pathological subtype of primary liver cancer, remains a major global health burden with poorly defined molecular mechanisms. Cell growth regulator 11 (CGR11), a novel secreted protein characterized by EF-hand motifs, has recently emerged as a potential extracellular signaling modulator in tumor biology. Although implicated in cancer cell proliferation and metastasis, its precise role and regulatory mechanisms in HCC progression have not been elucidated. Methods: We integrated bioinformatics analysis with single-cell transcriptomic profiling and CellChat-based intercellular communication mapping. CGR11 expression and localization were validated in tissue microarrays, HCC cell lines, and tumor specimens using immunohistochemical staining, qRT-PCR, and Western blotting. Results: CGR11 expression was markedly increased in HCC tissues relative to adjacent non-tumorous liver tissues and correlated with poor patient prognosis. Functional and mechanistic analyses demonstrated that CGR11 promotes HCC cell proliferation, invasion and tumor growth by inhibiting autophagy levels through activation of the PI3K/AKT signaling. Conversely, CGR11 knockdown restored autophagy and significantly suppressed tumor progression in both cellular and animal models. Conclusion: Our findings establish CGR11 as a novel oncogenic regulator that contributes to HCC progression by suppressing autophagy via PI3K/AKT activation. Targeting the CGR11-PI3K/AKT axis may therefore provide a promising avenue for precision therapeutic intervention in HCC.

Indexed as

autophagyCGR11hepatocellular carcinomamolecular mechanismPI3K/AKT

Identifiers

PMID41573680
PMCPMC12819743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.